Source: Annual Congress 2011 - Treating childhood asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. McIver, A. Emeryk, R. Klink, B. Schwab (Cambridge, United Kingdom; Lublin, Poland; Laon, France; Limburg (Lahn), Germany). Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma. Eur Respir J 2011; 38: Suppl. 55, 4823

Member's Comments

No comment yet.

Related content which might interest you: Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Fluticasone propionate/formoterol fumarate combination therapy is equally effective and well-tolerated when administered with or without a spacer device to patients with asthma Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007 Efficacy and safety of long-term therapy with Salamol combined with Beclason versus Salamol only in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients Source: Eur Respir J, 53 (6) 1801824; 10.1183/13993003.01824-2018 Year: 2019 Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Long-term treatment of aspirin-intolerante asthma with budesonide. Effectivity and safety Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010 Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Fluticasone propionate/formoterol fumarate combination therapy has comparable efficacy to its individual components administered concurrently Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011